Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Net loss	$ (687)	$ (1,159)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation and amortization	318	376
Accretion of financing instruments	160
Change in fair value of derivative liabilities	602	(14)
Impairment charge on investment in iBio, Inc.	139	0
Loss on sale of fixed assets	6	1
Compensation expense for employee stock options		10
Forbearance fee payable		1,000
Decrease (increase) in:
Accounts receivable	176	31
Inventories	(1,456)	2,656
Other current assets	47	(168)
Security deposits and other assets	50	(4)
(Decrease) increase in:
Accounts payable	39	(2,708)
Accrued expenses and other liabilities	(252)	(16)
Net cash (used in) provided by operating activities	(858)	14
Cash flows from investing activities:
Purchase of property and equipment	(21)	(82)
Proceeds from sale of property and equipment	18	12
Net cash used in investing activities	(3)	(70)
Cash flows from financing activities:
Advances under revolving credit facility	25,342
Repayments under revolving credit facility	(23,977)
Payments under term notes	(361)
Payments under capital lease obligations	(3)	(20)
Net cash provided by (used in) financing activities	1,001	(20)
Net increase (decrease) in cash	140	(76)
Cash at beginning of period	145	725
Cash at end of period	285	649
Interest	486	772
Income taxes	15	7
Financing on capitalized lease obligations	68
Convertible Debt [Member]
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Accretion of financing instruments		$ 9